<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-13T01:24:23Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:11351/6249" metadataPrefix="didl">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:11351/6249</identifier><datestamp>2024-12-13T11:05:21Z</datestamp><setSpec>com_2072_378070</setSpec><setSpec>com_2072_378040</setSpec><setSpec>col_2072_378092</setSpec></header><metadata><d:DIDL xmlns:d="urn:mpeg:mpeg21:2002:02-DIDL-NS" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="urn:mpeg:mpeg21:2002:02-DIDL-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/did/didl.xsd">
   <d:DIDLInfo>
      <dcterms:created xmlns:dcterms="http://purl.org/dc/terms/" xsi:schemaLocation="http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/dcterms.xsd">2023-11-08T10:20:16Z</dcterms:created>
   </d:DIDLInfo>
   <d:Item id="hdl_11351_6249">
      <d:Descriptor>
         <d:Statement mimeType="application/xml; charset=utf-8">
            <dii:Identifier xmlns:dii="urn:mpeg:mpeg21:2002:01-DII-NS" xsi:schemaLocation="urn:mpeg:mpeg21:2002:01-DII-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/dii/dii.xsd">urn:hdl:11351/6249</dii:Identifier>
         </d:Statement>
      </d:Descriptor>
      <d:Descriptor>
         <d:Statement mimeType="application/xml; charset=utf-8">
            <oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
               <dc:title>The Value of Case Reports in Systematic Reviews from Rare Diseases. The Example of Enzyme Replacement Therapy (ERT) in Patients with Mucopolysaccharidosis Type II (MPS-II)</dc:title>
               <dc:creator>Miguel-Huguet, Bernat</dc:creator>
               <dc:creator>Perez-Garcia, Jose Manuel</dc:creator>
               <dc:creator>Llombart-Cussac, Antonio</dc:creator>
               <dc:creator>Cortés Castan, Javier</dc:creator>
               <dc:creator>Pérez López, Jorge</dc:creator>
               <dc:creator>Sampayo-Cordero, Miguel</dc:creator>
               <dc:creator>Malfettone, Andrea</dc:creator>
               <dc:subject>Malalties rares</dc:subject>
               <dc:subject>Malalties congènites</dc:subject>
               <dc:subject>Enzims - Ús terapèutic</dc:subject>
               <dc:subject>ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Drug Therapy::Enzyme Therapy::Enzyme Replacement Therapy</dc:subject>
               <dc:subject>DISEASES::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Genetic Diseases, Inborn::Genetic Diseases, X-Linked::Mental Retardation, X-Linked::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Genetic Diseases, Inborn::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Genetic Diseases, Inborn::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Genetic Diseases, Inborn::Mucopolysaccharidosis II</dc:subject>
               <dc:subject>DISEASES::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Rare Diseases</dc:subject>
               <dc:subject>TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::farmacoterapia::terapia enzimática::tratamiento de sustitución enzimática</dc:subject>
               <dc:subject>ENFERMEDADES::enfermedades y anomalías neonatales congénitas y hereditarias::enfermedades genéticas congénitas::enfermedades genéticas ligadas al cromosoma X::retraso mental ligado al cromosoma X::enfermedades y anomalías neonatales congénitas y hereditarias::enfermedades genéticas congénitas::enfermedades y anomalías neonatales congénitas y hereditarias::enfermedades genéticas congénitas::enfermedades y anomalías neonatales congénitas y hereditarias::enfermedades genéticas congénitas::mucopolisacaridosis II</dc:subject>
               <dc:subject>ENFERMEDADES::afecciones patológicas, signos y síntomas::procesos patológicos::atributos de la enfermedad::enfermedades raras</dc:subject>
               <dc:description>Informe de un caso; Enfermedad rara; Revisión sistemática</dc:description>
               <dc:description>Informe d'un cas; Malaltia rara; Revisió sistemàtica</dc:description>
               <dc:description>Case report; Rare disease; Systematic review</dc:description>
               <dc:description>Background: Case reports are usually excluded from systematic reviews. Patients with rare diseases are more dependent on novel individualized strategies than patients with common diseases. We reviewed and summarized the novelties reported by case reports in mucopolysaccharidosis type II (MPS-II) patients treated with enzyme replacement therapy (ERT). Methods: We selected the case reports included in a previous meta-analysis of patients with MPS-II treated with ERT. Later clinical studies evaluating the same topic of those case reports were reported. Our primary aim was to summarize novelties reported in previous case reports. Secondary objectives analyzed the number of novelties evaluated in subsequent clinical studies and the time elapsed between the publication of the case report to the publication of the clinical study. Results: We identified 11 innovative proposals in case reports that had not been previously considered in clinical studies. Only two (18.2%) were analyzed in subsequent nonrandomized cohort studies. The other nine novelties (81.8%) were analyzed in later case reports (five) or were not included in ulterior studies (four) after more than five years from their first publication. Conclusions: Case reports should be included in systematic reviews of rare disease to obtain a comprehensive summary of the state of research and offer valuable information for healthcare practitioners.</dc:description>
               <dc:description>This research received no external funding.</dc:description>
               <dc:date>2023-11-08T10:20:16Z</dc:date>
               <dc:date>2023-11-08T10:20:16Z</dc:date>
               <dc:date>2021-09-01T10:44:29Z</dc:date>
               <dc:date>2021-09-01T10:44:29Z</dc:date>
               <dc:date>2020-09-10</dc:date>
               <dc:type>info:eu-repo/semantics/article</dc:type>
               <dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
               <dc:identifier>http://hdl.handle.net/11351/6249</dc:identifier>
               <dc:relation>International Journal Of Environmental Research And Public Health;17(18)</dc:relation>
               <dc:relation>https://www.mdpi.com/1660-4601/17/18/6590</dc:relation>
               <dc:rights>Attribution 4.0 International</dc:rights>
               <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
               <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
               <dc:publisher>MDPI</dc:publisher>
               <dc:source>Scientia</dc:source>
            </oai_dc:dc>
         </d:Statement>
      </d:Descriptor>
   </d:Item>
</d:DIDL></metadata></record></GetRecord></OAI-PMH>